Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due

 

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI and is the only inhibitor with activity against T3151 mutation. The impact of ponatinib on cardiovascular events was first evaluated in the PACE trial. We therefore report and discuss most relevant evidence currently available on cardiovascular events associated with the use of ponatinib. Though many exams can be used for diagnosis and follow-up of this kind of cardiotoxicity, echocardiography seems to have a pivotal role thanks to its feasibility, availability, and low cost.

PMID: 32026180 [PubMed - as supplied by publisher]

13:27

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:27

In reply to this message

pubmed: ctoall&ca or conall

An Incorrect Impression of Dose Versus the Ischemic Cardiac Toxicity Risk Profile for Breast and Chest Wall Radiation Therapy.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

An Incorrect Impression of Dose Versus the Ischemic Cardiac Toxicity Risk Profile for Breast and Chest Wall Radiation Therapy.

Int J Radiat Oncol Biol Phys. 2020 02 01;106(2):451-452

Authors: Sarkar B

PMID: 31928645 [PubMed - indexed for MEDLINE]

8 February 2020

12:55

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:55

In reply to this message

pubmed: caandvteortroorpul

High concentration of the plasma microparticles for venous thromboembolism associated with lung cancer.

Related Articles

High concentration of the plasma microparticles for venous thromboembolism associated with lung cancer.

Clin Respir J. 2020 Feb 07;:

Authors: Wang M, Huang X, Zhu M, Zhang S, Zhang Y